Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.jublhs.com
Global Number of Employees (Latest): 650
Year Founded: 1921
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Jubilant HollisterStier LLC provides contract manufacturing of commercial sterile and non-sterile products for pharmaceutical and biopharmaceutical industries. It offers sterile manufacturing services for phase I through commercial liquid and lyophilized products in vials and ampoules, as well as ophthalmic and otic solutions, ointments, and suspensions in bottles and tubes; and non-sterile manufacturing services for ointment, cream, and liquid products in bottles, tubes, jars, suppositories, and applicators. The company also provides clinical trial manufacturing (CTM) services, such as CTM sterile filling and CTM lyophilization; and support services, including validation, quality unit, full service laboratory, regulatory affairs, project management, and client notification system. Jubilant HollisterStier LLC was formerly known as Hollister-Stier Laboratories, LLC and changed its name to Jubilant HollisterStier LLC in April 2007. The company was founded in 1921 and is based in Spokane, Washington with facilities in Spokane, Washington; Montreal, Canada; and India. Jubilant HollisterStier LLC operates as a subsidiary of Jubilant Life Sciences Limited.


Financial Information (Currency: CAD, in mm)
Total Revenue
 206.7
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 650
Net Debt
-
U.S. Number of Employees 2021
 1,197
U.S. Number of Employees 2020
 1,071
U.S. Last Year Employee Growth %
 11.8
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Morales, Marcelo A.
Chief Executive Officer
Preti, Chris 
President
Wood-Gaines, Kirk
Vice President of Human Resources and Communications
Wright, Jack 
Vice President of Sales & Marketing
Arora, Amit D.
C.M.O


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
3525 North Regal Street | Spokane, WA | 99207-5788 | United States
Phone: 509 489 5656   Fax: 509 484 4320

Parent Company
Jubilant Pharmova Limited (BSE:530019)

Prior Investors
Windward Capital Partners


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-24-2007
Jun-1-2007
Merger/Acquisition
Target
Jubilant HollisterStier LLC
Jubilant Organosys Limited (nka:Jubilant Pharmova Limited (BSE:530019))
Windward Capital Partners
122.00
Feb-26-1999
Aug-25-1999
Merger/Acquisition
Target
Hollister-Stier Laboratories, LLC (nka:Jubilant HollisterStier LLC)
Windward Capital Partners
Bayer Aktiengesellschaft (XTRA:BAYN)
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Mar-16-2023
Business Expansions
Jubilant HollisterStier Announces Capacity Expansion At the Montreal Manufacturing Facility
Mar-16-2023
Executive/Board Changes - Other
Jubilant HollisterStier LLC Appoints Chris Preti as President
May-28-2022
Business Expansions
Jubilant HollisterStier LLC Enters into Cooperative Agreement of $149.6 Million with US Government to Expand Critical Vaccine Manufacturing Capacity
Nov-11-2021
Business Expansions
Jubilant Hollisterstier Llc, Usa, Announces Expansion of Its Manufacturing Facility
Jun-15-2021
Client Announcements
Jubilant Hollisterstier LLC Enters into Manufacturing Partnership

M&A Advisors
CIBC World Markets Corp., Oppenheimer & Co. Inc.


Advisors
M&A Advisors
CIBC World Markets Corp., Oppenheimer & Co. Inc.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 04:14 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC
Reports
34
The Insight Partners
The Insight Partners Research Team
Aug 31, 2023 02:16 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC. in Global Lyophilization Services For Biopharmaceuticals Market to 2028
Notes
5
GlobalData

Aug 29, 2023 01:47 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
16
GlobalData

Jun 15, 2023 02:08 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC
Reports
35
GlobalData

May 17, 2023 06:29 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
16
GlobalData

Mar 15, 2023 12:25 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC
Reports
33
GlobalData

Feb 10, 2023 05:20 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
16
GlobalData

Dec 14, 2022 07:32 PM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC
Reports
33
GlobalData

Nov 10, 2022 04:48 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
16
GlobalData

Sep 16, 2022 06:50 AM
Jubilant HollisterStier LLC
Jubilant HollisterStier LLC
Reports
33


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
0.9% Sodium Chloride Injection USP, Ampoules, Creams and Liquids, Ointments, Sterile Injectables


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-01-2019
Jul-30-2019
Zyla Life Sciences
SEC
8-K (1.01)
28 KB
Jun-25-2013
Jun-21-2013
Jubilant HollisterStier LLC
SEC
8-K (1.01)
14 KB
Dec-22-2010
Dec-16-2010
Jubilant HollisterStier LLC
SEC
8-K (1.01)
19 KB

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Morales, Marcelo A.
Chief Executive Officer
509 489 5656
509 484 4320
-
Preti, Chris 
President
509 489 5656
509 484 4320

Wood-Gaines, Kirk
Vice President of Human Resources and Communications
509 489 5656
509 484 4320
-
Wright, Jack 
Vice President of Sales & Marketing
509 489 5656
509 484 4320

Arora, Amit D.
C.M.O
509 489 5656
509 484 4320
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
